Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:PCVX NASDAQ:PRAX NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$44.01+17.7%$30.80$22.24▼$46.00$2.22B0.541.16 million shs2.78 million shsPCVXVaxcyte$60.67+6.5%$52.16$29.08▼$65.00$8.22B1.221.85 million shs1.51 million shsPRAXPraxis Precision Medicines$323.95+3.3%$312.45$37.19▼$366.52$8.74B2.74574,576 shs579,503 shsPTGXProtagonist Therapeutics$140.85+7.1%$107.91$49.38▼$141.08$8.46B1.79791,012 shs1.37 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+17.71%+18.59%+55.57%+30.32%+24.99%PCVXVaxcyte+6.51%+4.37%+28.10%+0.95%+89.59%PRAXPraxis Precision Medicines+3.33%-3.24%+27.54%+1.16%+593.98%PTGXProtagonist Therapeutics+7.11%+14.90%+44.64%+37.97%+182.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$44.01+17.7%$30.80$22.24▼$46.00$2.22B0.541.16 million shs2.78 million shsPCVXVaxcyte$60.67+6.5%$52.16$29.08▼$65.00$8.22B1.221.85 million shs1.51 million shsPRAXPraxis Precision Medicines$323.95+3.3%$312.45$37.19▼$366.52$8.74B2.74574,576 shs579,503 shsPTGXProtagonist Therapeutics$140.85+7.1%$107.91$49.38▼$141.08$8.46B1.79791,012 shs1.37 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+17.71%+18.59%+55.57%+30.32%+24.99%PCVXVaxcyte+6.51%+4.37%+28.10%+0.95%+89.59%PRAXPraxis Precision Medicines+3.33%-3.24%+27.54%+1.16%+593.98%PTGXProtagonist Therapeutics+7.11%+14.90%+44.64%+37.97%+182.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$42.56-3.30% DownsidePCVXVaxcyte 2.63Moderate Buy$86.0041.75% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$569.6375.84% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$116.93-16.98% DownsideCurrent Analyst Ratings BreakdownLatest AGIO, PRAX, PTGX, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026AGIOAgios Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$28.00 ➝ $32.007/7/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $41.007/7/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $46.007/7/2026PTGXProtagonist Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $145.007/1/2026PTGXProtagonist Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/24/2026AGIOAgios Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/11/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$36.00 ➝ $31.006/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$66.05M39.63N/AN/A$20.46 per share2.15PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/APRAXPraxis Precision Medicines$8.55M1,056.34N/AN/A$34.85 per share9.30PTGXProtagonist Therapeutics$46.02M196.83N/AN/A$9.83 per share14.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest AGIO, PRAX, PTGX, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026PCVXVaxcyte-$2.0556N/AN/AN/A$12.50 millionN/A8/5/2026Q2 2026PTGXProtagonist Therapeutics$2.11N/AN/AN/A$190.30 millionN/A8/3/2026Q2 2026PRAXPraxis Precision Medicines-$3.6683N/AN/AN/A$1.25 millionN/A7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6728N/AN/AN/A$26.42 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59PCVXVaxcyteN/A7.497.49PRAXPraxis Precision MedicinesN/A15.8815.88PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/APCVXVaxcyte96.78%PRAXPraxis Precision Medicines67.84%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%PCVXVaxcyte3.30%PRAXPraxis Precision Medicines3.00%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableAGIO, PRAX, PTGX, and PCVX HeadlinesRecent News About These CompaniesWhy Protagonist Therapeutics, Inc.’s (PTGX) Stock Is Up 5.03%July 7 at 2:16 PM | aaii.comAPTGX Stock Surges 64% in Six Months: What Is Driving the Rally?July 7 at 12:15 PM | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $145.00 Price Target at Truist FinancialJuly 7 at 9:09 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $145.00 at Truist FinancialJuly 7 at 8:35 AM | marketbeat.comWhy Wall Street’s wrong for loving Protagonist Therapeutics stockJuly 2, 2026 | msn.comProtagonist Therapeutics Reports Granting of Inducement AwardsJuly 1, 2026 | accessnewswire.comAPictet Asset Management Holding SA Boosts Stock Position in Protagonist Therapeutics, Inc. $PTGXJune 30, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - Should You Buy?June 29, 2026 | marketbeat.comLouisiana State Employees Retirement System Makes New $2.75 Million Investment in Protagonist Therapeutics, Inc. $PTGXJune 29, 2026 | marketbeat.comWilliam Waddill Sells 9,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) StockJune 27, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Cut to "Buy" at Wall Street ZenJune 27, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Lowered to "Buy" Rating by Wall Street ZenJune 27, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesJune 26, 2026 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 24, 2026 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Purchased by Perceptive Advisors LLCJune 18, 2026 | marketbeat.comElmind Capital LP Takes $3.32 Million Position in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comEversept Partners LP Takes Position in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comCommodore Capital LP Has $39.30 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comProtagonist Therapeutics Reports Granting of Inducement AwardsJune 16, 2026 | accessnewswire.comAProtagonist Therapeutics (NASDAQ:PTGX) Hits New 52-Week High - Time to Buy?June 16, 2026 | marketbeat.comNEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGXJune 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGIO, PRAX, PTGX, and PCVX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$44.01 +6.62 (+17.71%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$43.95 -0.06 (-0.14%) As of 07/7/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Vaxcyte NASDAQ:PCVX$60.67 +3.71 (+6.51%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$59.98 -0.69 (-1.14%) As of 07/7/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Praxis Precision Medicines NASDAQ:PRAX$323.95 +10.45 (+3.33%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$329.75 +5.80 (+1.79%) As of 07/7/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$140.85 +9.35 (+7.11%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$137.97 -2.88 (-2.04%) As of 07/7/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
